RxDoctor Payments Data

Nathalie Rioux, MD

Glaucoma Specialist · Greenfield, MANPI 1164510095

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,031 of the $1,173 with a category attached, or 87.9%. 12 manufacturers reported payments, led by AbbVie at 28.1% of the total.

$1,173in general payments, 2019–2025

Across 50 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$330
  • Ocular Therapeutix, Inc.$265
  • Alcon$139
  • Aerie Pharmaceuticals, Inc.$101
  • Bausch & Lomb Americas Inc.$93
  • Oyster Point Pharma, Inc.$61
  • plus $184 from 6 others

What the payments were for

  • Food & beverage$1,03188%
  • Education$14212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few glaucoma specialist providers in Massachusettsto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$669,803
Medicare patients
1,787
Services billed
5,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost311$181,950
RestasisCyclosporine98$139,397
VyzultaLatanoprostene Bunod162$90,449
RocklatanNetarsudil Mesylat/Latanoprost67$39,652
Cyclosporine43$34,574
XiidraLifitegrast23$29,749
Timolol Maleate446$29,129
Alphagan PBrimonidine Tartrate49$26,780
Travoprost87$23,984
Brimonidine Tartrate215$23,798
CombiganBrimonidine Tartrate/Timolol36$18,573
Brinzolamide65$14,452
Latanoprost755$13,209
Prednisolone Acetate345$11,156
ZioptanTafluprost/Pf47$10,810

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$330$366,699494 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$93$120,198185 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$101$47,72881 claims
AlconSimbrinza, Azopt$139$10,53232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Massachusettson file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Greenfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →